Association of atorvastatin with the risk of hepatotoxicity: a pilot prescription sequence symmetry analysis

References

• Adams SP, Tsang M, Wright JM. Lipid-lowering efficacy of atorvastatin. Cochrane Database Syst Rev. 2015;12(3):Cd008226.25760954
   PubMed Web of Science ®Google Scholar
• Burnett JR, Wilcox LJ, Telford DE, et al. Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs. Arterioscler Thromb Vasc Biol. 1997;17(11):2589–2600.9409231
   PubMed Web of Science ®Google Scholar
• Duan HY, Liu DM, Qian P, et al. Effect of atorvastatin on plasma NT-proBNP and inflammatory cytokine expression in patients with heart failure. Genet Mol Res. 2015;14(4):15739–15748. doi:10.4238/2015.December.1.2526634541
   PubMed Web of Science ®Google Scholar
• Zhong P, Wu D, Ye X, et al. Secondary prevention of major cerebrovascular events with seven different statins: a multi-treatment meta-analysis. Drug Des Devel Ther. 2017;11:2517–2526. doi:10.2147/DDDT.S135785
   PubMed Web of Science ®Google Scholar
• Qiu S, Zhuo W, Sun C, Su Z, Yan A, Shen L. Effects of atorvastatin on chronic subdural hematoma: a systematic review. Medicine. 2017;96(26):e7290. doi:10.1097/MD.000000000000729028658127
   PubMed Web of Science ®Google Scholar
• Salagre E, Fernandes BS, Dodd S, Brownstein DJ, Berk M. Statins for the treatment of depression: a meta-analysis of randomized, double-blind, placebo-controlled trials. J Affect Disord. 2016;200:235–242. doi:10.1016/j.jad.2016.04.04727148902
   PubMed Web of Science ®Google Scholar
• Archibugi L, Arcidiacono PG, Capurso G. Statin use is associated to a reduced risk of pancreatic cancer: a meta-analysis. Dig Liver Dis. 2019;51(1):28–37. doi: 10.1016/j.dld.2018.09.007
   Google Scholar
• Liu LY, Liu Y, Wu MY, Sun YY, Ma FZ. Efficacy of atorvastatin on the prevention of contrast-induced acute kidney injury: a meta-analysis. Drug Des Devel Ther. 2018;12:437–444. doi:10.2147/DDDT.S149106
   PubMed Web of Science ®Google Scholar
• Li GM, Zhao J, Li B, et al. The anti-inflammatory effects of statins on patients with rheumatoid arthritis: a systemic review and meta-analysis of 15 randomized controlled trials. Autoimmun Rev. 2018;17(3):215–225. doi:10.1016/j.autrev.2017.10.01329353098
   PubMed Web of Science ®Google Scholar
• Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Atorvastatin: safety and tolerability. Expert Opin Drug Saf. 2010;9(4):667–674. doi:10.1517/14740338.2010.49538520553090
   PubMed Web of Science ®Google Scholar
• Indumathi C, Anusha N, Vinod KV, Santhosh S, Dkhar SA. Atorvastatin induced adverse drug reactions among South Indian Tamils. J Clin Diagn Res. 2017;11(7):Fc01–fc05. doi:10.7860/JCDR/2017/27223.10175
   PubMed Web of Science ®Google Scholar
• Rosenbaum D, Dallongeville J, Sabouret P, Bruckert E. Discontinuation of statin therapy due to muscular side effects: a survey in real life. Nutr Metab Cardiovasc Dis. 2013;23(9):871–875. doi:10.1016/j.numecd.2012.04.01222748604
   PubMed Web of Science ®Google Scholar
• McIver LA, Siddique MS. Atorvastatin. [Updated January 5, 2019]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430779/. Accessed June 6, 2019.
   Google Scholar
• Liu M, Alafris A, Longo AJ, Cohen H. Irreversible atorvastatin-associated hearing loss. Pharmacotherapy. 2012;32(2):e27–e34. doi:10.1002/PHAR.104022392429
   PubMed Web of Science ®Google Scholar
• Clarke AT, Johnson PC, Hall GC, Ford I, Mills PR. High dose atorvastatin associated with increased risk of significant hepatotoxicity in comparison to simvastatin in UK GPRD cohort. PLoS One. 2016;11(3):e0151587. doi:10.1371/journal.pone.015158726983033
   PubMed Web of Science ®Google Scholar
• Bjornsson ES. Hepatotoxicity of statins and other lipid-lowering agents. Liver Int. 2017;37(2):173–178. doi:10.1111/liv.1330827860156
   PubMed Web of Science ®Google Scholar
• Bjornsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol. 2012;56(2):374–380. doi:10.1016/j.jhep.2011.07.02321889469
   PubMed Web of Science ®Google Scholar
• Karahalil B, Hare E, Koc G, Uslu I, Senturk K, Ozkan Y. Hepatotoxicity associated with statins. Arh Hig Rada Toksikol. 2017;68(4):254–260. doi:10.1515/aiht-2017-68-299429337684
   PubMed Web of Science ®Google Scholar
• Westerholm B. The rationale for a post-marketing surveillance. Hum Reprod. 1987;2(1):41–44. doi:10.1093/oxfordjournals.humrep.a1364863571446
   PubMed Web of Science ®Google Scholar
• Huang YL, Moon J, Segal JB. A comparison of active adverse event surveillance systems worldwide. Drug Saf. 2014;37(8):581–596. doi:10.1007/s40264-014-0194-325022829
   PubMed Web of Science ®Google Scholar
• Coloma PM, Trifiro G, Schuemie MJ, et al. Electronic healthcare databases for active drug safety surveillance: is there enough leverage? Pharmacoepidemiol Drug Saf. 2012;21(6):611–621. doi:10.1002/pds.319722315152
   PubMed Web of Science ®Google Scholar
• Hallas J. Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis. Epidemiology. 1996;7(5):478–484.8862977
   PubMed Web of Science ®Google Scholar
• Lai EC, Pratt N, Hsieh CY, et al. Sequence symmetry analysis in pharmacovigilance and pharmacoepidemiologic studies. Eur J Epidemiol. 2017;32(7):567–582. doi:10.1007/s10654-017-0281-828698923
   PubMed Web of Science ®Google Scholar
• Pratt N, Chan EW, Choi NK, et al. Prescription sequence symmetry analysis: assessing risk, temporality, and consistency for adverse drug reactions across datasets in five countries. Pharmacoepidemiol Drug Saf. 2015;24(8):858–864. doi:10.1002/pds.378025907076
   PubMed Web of Science ®Google Scholar
• Pratt NL, Ilomaki J, Raymond C, Roughead EE. The performance of sequence symmetry analysis as a tool for post-market surveillance of newly marketed medicines: a simulation study. BMC Med Res Methodol. 2014;14:66. doi:10.1186/1471-2288-14-6624886247
   PubMed Web of Science ®Google Scholar
• Fang RF, Li JH, Zhang J, Gao SQ, Pan YT, Zhan SY. [Association between statins use and liver injury based on prescription sequence symmetry analysis]. Zhonghua Liu Xing Bing Xue Za Zhi. 2016;37(7):935–939. doi:10.3760/cma.j.issn.0254-6450.2016.07.00627453100
   PubMedGoogle Scholar
• Tyree PT, Lind BK, Lafferty WE. Challenges of using medical insurance claims data for utilization analysis. Am J Med Qual. 2006;21(4):269–275. doi:10.1177/106286060628877416849784
   PubMed Web of Science ®Google Scholar
• Petri H, Leufkens H, Naus J, Silkens R, van Hessen P, Urquhart J. Rapid method for estimating the risk of acutely controversial side effects of prescription drugs. J Clin Epidemiol. 1990;43(5):433–439.2324783
   PubMed Web of Science ®Google Scholar
• Yu YC, Mao YM, Chen CW, et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatol Int. 2017;11(3):221–241. doi:10.1007/s12072-017-9793-228405790
   PubMed Web of Science ®Google Scholar
• Chalasani NP, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, Fontana RJ. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109(7):950–966; quiz 967. doi:10.1038/ajg.2014.131
   PubMed Web of Science ®Google Scholar
• Hallas J, Gaist D, Bjerrum L. The waiting time distribution as a graphical approach to epidemiologic measures of drug utilization. Epidemiology. 1997;8(6):666–670.9345667
   PubMed Web of Science ®Google Scholar
• Hersom K, Neary MP, Levaux HP, Klaskala W, Strauss JS. Isotretinoin and antidepressant pharmacotherapy: a prescription sequence symmetry analysis. J Am Acad Dermatol. 2003;49(3):424–432.12963905
   PubMed Web of Science ®Google Scholar
• Kubota K. Symmetry analysis for monitoring safety of newly marketed drugs. Pharmacoepidemiol Drug Saf. 2016;25(3):349–351. doi:10.1002/pds.388626440748
   PubMed Web of Science ®Google Scholar
• Morris JA, Gardner MJ. Calculating confidence intervals for relative risks (odds ratios) and standardised ratios and rates. BMJ. 1988;296(6632):1313–1316. doi:10.1136/bmj.296.6632.13133133061
   PubMed Web of Science ®Google Scholar
• Perdices EV, Medina-Caliz I, Hernando S, et al. Hepatotoxicity associated with statin use: analysis of the cases included in the Spanish Hepatotoxicity Registry. Rev Esp Enferm Dig. 2014;106(4):246–254.25075655
   PubMed Web of Science ®Google Scholar
• Russo MW, Scobey M, Bonkovsky HL. Drug-induced liver injury associated with statins. Semin Liver Dis. 2009;29(4):412–422. doi:10.1055/s-0029-124001019826975
   PubMed Web of Science ®Google Scholar
• Pelli N, Setti M, Ceppa P, Toncini C, Indiveri F. Autoimmune hepatitis revealed by atorvastatin. Eur J Gastroenterol Hepatol. 2003;15(8):921–924. doi:10.1097/00042737-200308000-0001412867804
   PubMed Web of Science ®Google Scholar
• Fukunaga K, Nakagawa H, Ishikawa T, Kubo M, Mushiroda T. ABCB1 polymorphism is associated with atorvastatin-induced liver injury in Japanese population. BMC Genet. 2016;17(1):79. doi:10.1186/s12863-016-0390-527296832
   PubMed Web of Science ®Google Scholar
• Qi XF, Zheng L, Lee KJ, et al. HMG-CoA reductase inhibitors induce apoptosis of lymphoma cells by promoting ROS generation and regulating Akt, Erk and p38 signals via suppression of mevalonate pathway. Cell Death Dis. 2013;4:e518. doi:10.1038/cddis.2013.4423449454
   PubMed Web of Science ®Google Scholar
• Pal S, Ghosh M, Ghosh S, Bhattacharyya S, Sil PC. Atorvastatin induced hepatic oxidative stress and apoptotic damage via MAPKs, mitochondria, calpain and caspase12 dependent pathways. Food Chem Toxicol. 2015;83:36–47. doi:10.1016/j.fct.2015.05.01626051349
   PubMed Web of Science ®Google Scholar
• Hassan SS, Razzaque A, Ahmad Z, Pazdernik V, Amin SN. Does posttreatment thymoquinone reverse high-dose atorvastatin-induced hepatic oxidative injury in rats? Can J Physiol Pharmacol. 2018;96(1):51–59. doi:10.1139/cjpp-2017-059928968507
   PubMed Web of Science ®Google Scholar
• Nawarskas JJ. HMG-CoA reductase inhibitors and coenzyme Q10. Cardiol Rev. 2005;13(2):76–79. doi:10.1097/01.crd.0000154790.42283.a115705257
   PubMedGoogle Scholar
• Rundek T, Naini A, Sacco R, Coates K, DiMauro S. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. Arch Neurol. 2004;61(6):889–892. doi:10.1001/archneur.61.6.88915210526
   PubMedGoogle Scholar
• Deichmann R, Lavie C, Andrews S. Coenzyme q10 and statin-induced mitochondrial dysfunction. Ochsner J. 2010;10(1):16–21.21603349
   PubMedGoogle Scholar
• Pourmoghaddas M, Rabbani M, Shahabi J, Garakyaraghi M, Khanjani R, Hedayat P. Combination of atorvastatin/coenzyme Q10 as adjunctive treatment in congestive heart failure: a double-blind randomized placebo-controlled clinical trial. ARYA Atheroscler. 2014;10(1):1–5.24963306
   PubMedGoogle Scholar
• Lee YJ, Lee MG, Lim LA, Jang SB, Chung JY. Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects. Int J Clin Pharmacol Ther. 2010;48(1):36–45.20040338
   PubMed Web of Science ®Google Scholar
• Xu DY, Shu J, Huang QY, et al. Evaluation of the lipid lowering ability, anti-inflammatory effects and clinical safety of intensive therapy with Zhibitai, a Chinese traditional medicine. Atherosclerosis. 2010;211(1):237–241. doi:10.1016/j.atherosclerosis.2010.01.04420189174
   PubMed Web of Science ®Google Scholar
• Moriarty PM, Roth EM, Karns A, et al. Effects of Xuezhikang in patients with dyslipidemia: a multicenter, randomized, placebo-controlled study. J Clin Lipidol. 2014;8(6):568–575. doi:10.1016/j.jacl.2014.09.00225499939
   PubMed Web of Science ®Google Scholar
• Loch A, Bewersdorf JP, Kofink D, Ismail D, Abidin IZ, Veriah RS. Generic atorvastatin is as effective as the brand-name drug (LIPITOR((R))) in lowering cholesterol levels: a cross-sectional retrospective cohort study. BMC Res Notes. 2017;10(1):291. doi:10.1186/s13104-017-2617-628716156
   PubMedGoogle Scholar